JonesTrading analyst Soumit Roy raised the firm’s price target on Anavex (AVXL) to $80 from $40 and keeps a Buy rating on the shares after the company announced the Phase 2b/3 trial of oral ANAVEX2-73, or blarcamesine, for the treatment of mild cognitive impairment due to Alzheimer’s disease, AD, and mild AD met the primary endpoints. In Roy’s view, there is "a clear win shown by ADAS-Cog" and "markedly better safety" with Anavex’s oral drug than seen with Eisai (ESALY) and Biogen’s (BIIB) antibody.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AVXL:
- Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022
- Anavex Shoots Up After Positive Topline Data
- ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease
- Anavex phase 2B/3 study of blarcamesine met primary and key secondary endpoints
- Anavex Stock: Volatility Beckons but the Pipeline Has Big Potential, Says Analyst